133 related articles for article (PubMed ID: 7692199)
1. Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin's disease: possible synergy.
Matthews JH
Lancet; 1993 Oct; 342(8877):988. PubMed ID: 7692199
[No Abstract] [Full Text] [Related]
2. Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor.
Merdin A; Çakar MK; Dal MS; Mert D; Yıldız J; Başçı S; Bakırtaş M; Darçın T; Şahin D; Ulu BU; Yiğenoğlu TN; Batgi H; Tetik A; İskender D; Altuntaş F
J Oncol Pharm Pract; 2020 Jun; 26(4):929-932. PubMed ID: 31822199
[TBL] [Abstract][Full Text] [Related]
3. Intermittent G-CSF to maintain dose intensity of chemotherapy for Hodgkin's disease.
Clarke K; Grigg A
Leuk Lymphoma; 1995 Nov; 19(5-6):521-2. PubMed ID: 8590858
[No Abstract] [Full Text] [Related]
4. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
[TBL] [Abstract][Full Text] [Related]
5. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease.
Silvestri F; Fanin R; Velisig M; Barillari G; Virgolini L; Zaja F; Russo D; Baccarani M
Tumori; 1994 Dec; 80(6):453-8. PubMed ID: 7534963
[TBL] [Abstract][Full Text] [Related]
6. ABVD in the treatment of Hodgkin's disease.
Bonfante V; Santoro A; Viviani S; Valagussa P; Bonadonna G
Semin Oncol; 1992 Apr; 19(2 Suppl 5):38-44; discussion 44-5. PubMed ID: 1384143
[TBL] [Abstract][Full Text] [Related]
7. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
8. Acute promyelocytic leukemia following ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and radiotherapy for Hodgkin's disease.
Amadori S; Papa G; Anselmo AP; Fidani P; Mandelli F; Biagini C
Cancer Treat Rep; 1983 Jun; 67(6):603-4. PubMed ID: 6190561
[No Abstract] [Full Text] [Related]
9. Acute myeloid leukemia following therapy of Hodgkin's disease with radiotherapy and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).
Lipton JH; Gospodarowicz M; Reingold S
Hematol Oncol; 1996 Mar; 14(1):29-31. PubMed ID: 8613133
[TBL] [Abstract][Full Text] [Related]
10. Male infertility caused by the chemotherapy of Hodgkin's disease: MOPP versus ABVD.
Ragni G; Lombardi C; Santoro A; Bestetti O; Wyssling H
Acta Eur Fertil; 1983; 14(3):221-2. PubMed ID: 6199937
[No Abstract] [Full Text] [Related]
11. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study.
Minuk LA; Monkman K; Chin-Yee IH; Lazo-Langner A; Bhagirath V; Chin-Yee BH; Mangel JE
Leuk Lymphoma; 2012 Jan; 53(1):57-63. PubMed ID: 21740297
[TBL] [Abstract][Full Text] [Related]
12. [Results of the treatment of Hodgkin's disease stage III and IV using the ABVD and BACOP programs].
Leszko B; Słomkowski M; Przybyszewska M; Apel D; Pawelski S
Acta Haematol Pol; 1986; 17(3-4):81-90. PubMed ID: 2438894
[No Abstract] [Full Text] [Related]
13. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group.
Fryer CJ; Hutchinson RJ; Krailo M; Collins RD; Constine LS; Hays DM; Heller RM; Davis PC; Nachman J; O'Brien RT
J Clin Oncol; 1990 Dec; 8(12):1971-80. PubMed ID: 1700080
[TBL] [Abstract][Full Text] [Related]
14. MOPP, ABVD, or both to treat Hodgkin's disease.
Aisenberg AC
N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680765
[No Abstract] [Full Text] [Related]
15. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group.
Takenaka T; Mikuni C; Miura A; Sasaki T; Suzuki H; Hotta T; Hirano M; Fukuhara S; Sugiyama H; Nasu K; Dohi H; Kozuru M; Tomonaga M; Tajima K; Niimi M; Fukuda H; Mukai K; Shimoyama M
Jpn J Clin Oncol; 2000 Mar; 30(3):146-52. PubMed ID: 10798542
[TBL] [Abstract][Full Text] [Related]
16. Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease. A case report.
Joensuu H; Söderström KO; Nikkanen V
Cancer; 1986 Oct; 58(7):1437-40. PubMed ID: 2427187
[TBL] [Abstract][Full Text] [Related]
17. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
Chand VK; Link BK; Ritchie JM; Shannon M; Wooldridge JE
Leuk Lymphoma; 2006 Apr; 47(4):657-63. PubMed ID: 16690524
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of survival in Hodgkin's lymphoma.
Canellos GP; Niedzwiecki D; Johnson JL
N Engl J Med; 2009 Dec; 361(24):2390-1. PubMed ID: 20007568
[No Abstract] [Full Text] [Related]
19. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
[TBL] [Abstract][Full Text] [Related]
20. [Cardiogenic shock during polychemotherapy in a patient with Hodgkin's disease].
Drzewoski J; Chojnowski K; Olszańska-Skorek T; Krykowski E
Kardiol Pol; 1986; 29(8):555-9. PubMed ID: 2435945
[No Abstract] [Full Text] [Related]
[Next] [New Search]
